DEF: ENDRA Seeks Massive Share Increase, Officer Exculpation

ENDRA Life Sciences Inc. calls for its 2025 Annual Meeting to vote on proposals including a significant increase in authorized shares and officer liability limitations.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on December 9, 2025, at 10:00 a.m. Eastern Time.
• Stockholders will vote on the election of four director nominees to serve one-year terms.
• An advisory vote on executive compensation will be held.
• The appointment of RBSM LLP as the independent registered public accounting firm for 2025 is up for ratification.
• A proposal seeks to amend the Certificate of Incorporation to increase authorized common stock from 20,000,000 shares to 1,000,000,000 shares.
• Another proposal aims to amend the Certificate of Incorporation to exculpate certain officers, as permitted by recent changes to Delaware law.
• Stockholders will also vote on a second amendment to the 2016 Omnibus Incentive Plan, increasing the share pool by 3,200,000 shares.
• The Board of Directors unanimously recommends a vote FOR all six proposals.

Sentiment

Score: 2

Explanation: The company exhibits severe financial distress, evidenced by consistent net losses, a near-total loss of shareholder value (TSR from $100 to $0.03), and recent reverse stock splits. The proposed massive increase in authorized shares signals significant future dilution, and the stated potential strategic pivot towards cryptocurrency for a life sciences firm introduces extreme and questionable risks, indicating a highly unfavorable outlook for investors.

Positives

• The Board of Directors unanimously recommends approval for all proposals, indicating unified management and board direction.
• The proposed increase in authorized shares could provide flexibility for future capital raises and strategic corporate purposes, including potential acquisitions.
• The amendment to the 2016 Omnibus Incentive Plan aims to enhance the company's ability to attract, retain, and motivate qualified personnel through equity compensation.
• Officer exculpation is intended to help attract and retain key executive officers and potentially reduce litigation costs associated with frivolous lawsuits.

Negatives

• The proposal to increase authorized common stock from 20,000,000 to 1,000,000,000 shares represents a potential for extreme future dilution for current stockholders.
• The company has a history of consistent net losses: $(11.5) million in 2024, $(10.1) million in 2023, and $(13.2) million in 2022.
• Cumulative Total Shareholder Return (TSR) has been severely negative, with an initial $100 investment on December 31, 2021, valued at only $0.03 by December 31, 2024.
• Two reverse stock splits were effected in 2024 (one-for-fifty in August and one-for-thirty-five in November), indicating significant share price depreciation and financial distress.
• The officer exculpation amendment, while permitted by law, limits the monetary liability of certain officers for breaches of fiduciary duty, which could be viewed negatively by some investors regarding accountability.

Risks

• Future issuances of common stock or securities convertible into common stock could have a dilutive effect on earnings per share, book value per share, voting power, and percentage interest of holdings of current stockholders.
• The availability of additional shares for issuance could, under certain circumstances, discourage or make more difficult efforts to obtain control of the company, potentially acting as an anti-takeover measure.
• The officer exculpation amendment does not eliminate or limit liability for breaches of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or transactions from which an officer derived an improper personal benefit, nor for claims brought by or in the right of the corporation (derivative claims).
• The company's stated potential use of capital for 'digital asset treasury operations and the accumulation of cryptocurrency' introduces significant new and potentially volatile risks unrelated to its core life sciences business.

Future Outlook

The company has no current plans, arrangements, or understandings for equity transactions related to the proposed increase in authorized shares. However, any additional capital raised through equity transactions may be used to fund the company's digital asset treasury operations and the accumulation of cryptocurrency. The company expects to ask stockholders for approval of a new equity plan in 2026.

Management Comments

• "We are using the Notice and Access method of providing proxy materials to you via the internet. We believe that this process should provide you with a convenient and quick way to access your proxy materials and vote your shares, while allowing us to conserve natural resources and reduce the costs of printing and distributing the proxy materials." Richard Jacroux, CFO
• "The Board believes that it is in the best interests of the Company to retain flexibility in determining whether to separate or combine the roles of Chairman and Chief Executive Officer based on our circumstances." (Regarding Alexander Tokman serving as both Chairman and CEO)
• "The Board believes that the increase in authorized shares of common stock would be beneficial for ensuring that an adequate number of shares of common stock are available for potential future corporate purposes and enabling equity transactions to raise additional capital."
• "The Board believes that the interests of the Company and its stockholders will be advanced if we can continue to offer our officers, non-employee directors, key employees, consultants, and advisors the opportunity to acquire or increase a direct proprietary interest in the Company." (Regarding the 2016 Plan Amendment)
• "The Board of Directors adopted and declared the advisability of the Exculpation Amendment, taking into account the narrow class and type of claims that certain of our officers would be exculpated from monetary damages for, the limited number of our officers that would be covered by the proposed Exculpation Amendment, and the potential benefits the Board of Directors believed would accrue to us from providing such exculpation, including, without limitation, the ability to attract and retain key executive officers and the potential to reduce litigation costs associated with frivolous lawsuits."

Industry Context

The company, a life sciences firm, is proposing a highly unusual strategic shift by indicating that future capital raises may be used to fund 'digital asset treasury operations and the accumulation of cryptocurrency.' This deviates significantly from typical industry trends for biotechnology or medical device companies, which usually focus on R&D, clinical trials, and commercialization of their core products. This pivot introduces a new, speculative element to the company's strategy, potentially impacting its perceived focus and risk profile within the life sciences sector.

Comparison to Industry Standards

• The company's stated potential use of capital for 'digital asset treasury operations and the accumulation of cryptocurrency' is highly unconventional for a life sciences company. This contrasts sharply with industry peers like Medtronic, Johnson & Johnson, or smaller biotech firms, which typically reinvest capital into research and development, clinical trials, manufacturing, or market expansion for their medical products.
• The company's cumulative Total Shareholder Return (TSR) of $0.03 from an initial $100 investment over three years (2021-2024) is significantly below industry benchmarks and the performance of successful life sciences companies, which often aim for substantial capital appreciation driven by product development and market penetration.
• The occurrence of two reverse stock splits in 2024 (1-for-50 and 1-for-35) is a strong indicator of severe financial distress and share price erosion, a situation generally avoided by healthy, growing companies in the life sciences sector.

Management Changes

Corporate Governance

Related Party Transactions

• On May 2, 2023, Anthony DiGiandomenico, a director, purchased 48 shares of common stock and 24 warrants for approximately $100,000 in a public offering.
• From October 17, 2023, to August 13, 2024, the company had a consulting agreement with Alex Tokman (then a director, now CEO), paying him $75,000 in 2024 for commercialization services.
• Since March 24, 2024, the company has contracted with Impact Solve, LLC (owned by Richard Jacroux, CFO) for accounting and CFO services, paying a base monthly fee of $8,650 plus $150 per hour for hours exceeding 20 per week.
• On October 15, 2025, Anthony DiGiandomenico participated in a private placement, purchasing $500,000 worth of common stock and warrants at a price of $7.06 per share, consistent with terms for other investors but at a higher price due to Nasdaq rules.

Stakeholder Impact

• Shareholders face significant potential dilution if the proposed increase in authorized shares is approved and subsequently utilized for capital raises.
• Existing shareholders have experienced substantial value erosion, with a near-total loss of investment based on the cumulative Total Shareholder Return.
• The officer exculpation proposal could limit shareholders' ability to seek monetary damages from certain officers for specific breaches of fiduciary duty, potentially impacting accountability.
• Employees, officers, non-employee directors, consultants, and advisors could benefit from the expanded 2016 Omnibus Incentive Plan, which aims to attract and retain talent.
• The company's strategic shift towards 'digital asset treasury operations and the accumulation of cryptocurrency' could alter its risk profile and investor base, potentially alienating traditional life sciences investors while attracting speculative capital.

Next Steps

• Stockholders will vote on the proposed amendments and elections at the Annual Meeting on December 9, 2025.
• The company will announce the voting results in a Current Report on Form 8-K filed with the SEC within four business days following the meeting.
• The Board of Directors intends to update the non-employee director compensation policy in light of the recent reverse stock splits.
• The company expects to seek stockholder approval for a new equity plan in 2026.
• If approved, the increase in authorized shares will be implemented by filing the Certificate of Amendment with the Delaware Secretary of State, enabling potential future equity transactions.

Key Dates

Recommendation

The company's financial performance is dire, marked by consistent net losses and a near-total loss of shareholder value, as evidenced by the cumulative Total Shareholder Return plummeting from $100 to $0.03. The recent implementation of two reverse stock splits underscores severe financial distress. The proposal to increase authorized shares by 50-fold (from 20 million to 1 billion) signals an urgent need for capital and portends massive future dilution for existing shareholders. Most critically, the stated potential use of capital for 'digital asset treasury operations and the accumulation of cryptocurrency' for a life sciences company is an extremely speculative and unconventional strategic pivot, diverting from its core business and introducing significant, unrelated risks. This combination of abysmal performance, highly dilutive actions, and a questionable strategic direction makes the stock a strong sell.

Keywords

ENDRA Life Sciences, Proxy Statement, Annual Meeting, Stockholder Vote, Authorized Shares Increase, Officer Exculpation, Equity Incentive Plan, Dilution, Capital Raise, Corporate Governance, Executive Compensation, Financial Performance, Reverse Stock Split, Cryptocurrency